Reaffirmed: Alder BioPharmaceuticals (NASDAQ:ALDR) “Outperform” Rating Maintained by BMO Capital; $23 Target in Place

August 9, 2018 - By Margaret Guttierez

Alder BioPharmaceuticals (NASDAQ:ALDR) Rating Reaffirmed

Stock analysts at BMO Capital now has a $23 price target on Alder BioPharmaceuticals (NASDAQ:ALDR). BMO Capital and their recent price target means a potential upside of 15.58 % from the company’s last stock close price. The rating has been revealed in analysts note on 8 August.

Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Ratings Coverage

Among 5 analysts covering Alder BioPharmaceuticals (NASDAQ:ALDR), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Alder BioPharmaceuticals has $30 highest and $17 lowest target. $25.20’s average target is 26.63% above currents $19.9 stock price. Alder BioPharmaceuticals had 6 analyst reports since April 24, 2018 according to SRatingsIntel. BMO Capital Markets maintained Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) on Wednesday, August 8 with “Outperform” rating. BMO Capital Markets maintained the stock with “Outperform” rating in Wednesday, May 9 report. The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has “Buy” rating given on Wednesday, June 27 by Needham.

The stock increased 2.58% or $0.5 during the last trading session, reaching $19.9. About 1.15 million shares traded or 14.60% up from the average. Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has declined 8.80% since August 9, 2017 and is downtrending. It has underperformed by 21.37% the S&P500.

Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. The company has market cap of $1.35 billion. The companyÂ’s lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It currently has negative earnings. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis.

More important recent Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed’s Antibiotic Faces FDA Panel” on August 07, 2018, also Profitconfidential.com published article titled: “ALDR Stock Inches Away From Breaking Out Toward Higher Prices”, Seekingalpha.com published: “Premarket analyst action – healthcare” on August 07, 2018. More interesting news about Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) was released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For August 6, 2018” with publication date: August 06, 2018.

Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.